The Intersection of DNA Damage Response and Ferroptosis-A Rationale for Combination Therapeutics

被引:27
|
作者
Chen, Po-Han [1 ,2 ,3 ]
Tseng, Watson Hua-Sheng [1 ,2 ,4 ]
Chi, Jen-Tsan [1 ,2 ]
机构
[1] Duke Univ, Sch Med, Dept Mol Genet & Microbiol, Durham, NC 27710 USA
[2] Duke Univ, Sch Med, Ctr Genom & Computat Biol, Durham, NC 27710 USA
[3] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06511 USA
[4] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan
来源
BIOLOGY-BASEL | 2020年 / 9卷 / 08期
关键词
ferroptosis; DNA damage; ATM; ATR; p53; MDM2; MDMX; CELL-DEATH; ATM ACTIVATION; P53; ACTIVATION; ATAXIA-TELANGIECTASIA; ONCOPROTEIN MDM2; HIPPO PATHWAY; PROTEIN; PHOSPHORYLATION; PROMOTES; METABOLISM;
D O I
10.3390/biology9080187
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ferroptosis is a novel form of iron-dependent cell death characterized by lipid peroxidation. While the importance and disease relevance of ferroptosis are gaining recognition, much remains unknown about its interaction with other biological processes and pathways. Recently, several studies have identified intricate and complicated interplay between ferroptosis, ionizing radiation (IR), ATM (ataxia-telangiectasia mutated)/ATR (ATM and Rad3-related), and tumor suppressor p53, which signifies the participation of the DNA damage response (DDR) in iron-related cell death. DDR is an evolutionarily conserved response triggered by various DNA insults to attenuate proliferation, enable DNA repairs, and dispose of cells with damaged DNA to maintain genome integrity. Deficiency in proper DDR in many genetic disorders or tumors also highlights the importance of this pathway. In this review, we will focus on the biological crosstalk between DDR and ferroptosis, which is mediated mostly via noncanonical mechanisms. For clinical applications, we also discuss the potential of combining ionizing radiation and ferroptosis-inducers for synergistic effects. At last, various ATM/ATR inhibitors under clinical development may protect ferroptosis and treat many ferroptosis-related diseases to prevent cell death, delay disease progression, and improve clinical outcomes.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 50 条
  • [1] CtIP: A DNA damage response protein at the intersection of DNA metabolism
    Makharashvili, Nodar
    Paull, Tanya T.
    DNA REPAIR, 2015, 32 : 75 - 81
  • [2] Targeting ATR in DNA damage response and cancer therapeutics
    Fokas, Emmanouil
    Prevo, Remko
    Hammond, Ester M.
    Brunner, Thomas B.
    McKenna, W. Gillies
    Muschel, Ruth J.
    CANCER TREATMENT REVIEWS, 2014, 40 (01) : 109 - 117
  • [3] Strategies for targeting the DNA damage response for cancer therapeutics
    Zhang, Dan
    Wang, Hai-Bo
    Brinkman, Kathryn L.
    Han, Su-Xia
    Xu, Bo
    CHINESE JOURNAL OF CANCER, 2012, 31 (08) : 359 - 363
  • [4] Hypofractionation: can the DNA damage response deliver a biological rationale?
    Rothkamm, K.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S340 - S340
  • [5] Linking DNA Damage Response to Ferroptosis for Leukemia Stem Cell Eradication
    Malik, Bilal
    Hassan, Nunki
    Wang, Jenny Y.
    BLOOD, 2023, 142
  • [6] Intersection of the fragile X-related disorders and the DNA damage response
    Kumari, Daman
    Grant-Bier, Jessalyn
    Kadyrov, Farid
    Usdin, Karen
    DNA REPAIR, 2024, 144
  • [7] Development of a DNA damage response (DDR) therapeutics platform for oncology.
    Das, Debanu
    Duncton, Matthew
    Pellicena, Patricia
    Deacon, Ashley
    Wilson, David
    Georgiadis, Millie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] FIRST-IN-CLASS CANCER THERAPEUTICS TARGETING THE DNA DAMAGE RESPONSE
    Robertson, Adam
    Prikrylova, Terezia
    Lancero, Hope
    Wilson, Christy
    Petritsch, Claudia
    NEURO-ONCOLOGY, 2023, 25
  • [9] At the intersection of DNA damage and immune responses
    Bednarski, Jeffrey J.
    Sleckman, Barry P.
    NATURE REVIEWS IMMUNOLOGY, 2019, 19 (04) : 231 - 242
  • [10] Understanding DNA Damage Response and DNA Repair Pathways: Applications to More Targeted Cancer Therapeutics
    Kinsella, Timothy J.
    SEMINARS IN ONCOLOGY, 2009, 36 (02) : S42 - S51